Tvardi Therapeutics, Incorporated
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet needs. Founded in 2017 and based in Houston, Texas, the company aims to address diseases such as idiopathic pulmonary fibrosis and hepatocellular carcinoma through its Phase 2 clinical trials. The company's mission is to develop safe and effective STAT3 inhibitors to improve patient outcomes across various fibrotic and cancerous conditions.
Industries
Nr. of Employees
small (1-50)
Tvardi Therapeutics, Incorporated
3 Sugar Creek Ctr Blvd, Ste 525, Sugar Land, TX 77478
Patents
Products
TTI-101
Oral small-molecule inhibitor that targets STAT3 signaling, developed for treatment of fibrosis-driven diseases and certain cancers; progressed into Phase 1 and Phase 2 clinical trials.
TTI-101
Oral small-molecule inhibitor that targets STAT3 signaling, developed for treatment of fibrosis-driven diseases and certain cancers; progressed into Phase 1 and Phase 2 clinical trials.
Services
Planning and execution of early- and mid-stage clinical trials to evaluate safety, pharmacology, and preliminary efficacy of oral small-molecule STAT3 inhibitors in oncology and fibrosis-driven indications.
Planning and execution of early- and mid-stage clinical trials to evaluate safety, pharmacology, and preliminary efficacy of oral small-molecule STAT3 inhibitors in oncology and fibrosis-driven indications.
Expertise Areas
- Clinical trial management (Phase 1 and Phase 2)
- Small-molecule drug discovery and development
- Translational research and preclinical modeling
- Fibrosis-driven disease therapeutics
Key Technologies
- Small-molecule STAT3 inhibition
- Oral systemic small-molecule formulation
- Phase 1/Phase 2 clinical trial methodologies
- IND-enabling preclinical studies
News & Updates
Tvardi Therapeutics announced its participation in upcoming investor conferences on May 20, 2025.
On May 13, 2025, Tvardi Therapeutics announced its first quarter 2025 results and provided a business update.
On May 6, 2025, Tvardi Therapeutics announced its presentation at the ATS 2025 conference.
On April 15, 2025, Tvardi announced the closing of its merger with Cara Therapeutics.
On May 27, 2025, Tvardi announced the completion of enrollment in its Phase 2 trial for IPF.
Tvardi was named one of the most promising biotech companies in 2021 by Fierce Biotech.
Tvardi Therapeutics announced its participation in upcoming investor conferences on May 20, 2025.
On May 13, 2025, Tvardi Therapeutics announced its first quarter 2025 results and provided a business update.
On May 6, 2025, Tvardi Therapeutics announced its presentation at the ATS 2025 conference.
On April 15, 2025, Tvardi announced the closing of its merger with Cara Therapeutics.
On May 27, 2025, Tvardi announced the completion of enrollment in its Phase 2 trial for IPF.
Tvardi was named one of the most promising biotech companies in 2021 by Fierce Biotech.